Nebulized Beclometasone Dipropionate Improves Nasal Patency in Children With Allergic Rhinitis

PHASE4CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

July 31, 2017

Conditions
Allergic Rhinitis
Interventions
DRUG

Nasal Beclomethasone Dipropionate

Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of nebulized Beclomethasone Dipropionate nasal spray for 21 days.

DRUG

CERCHIO 10 mg/ml OS

For Children \< 12 years old 10 drops die (5 mg die) for 21 days. For Children \> 12 years old 20 drops die (10 mg die) for 21 days.

Trial Locations (2)

90146

Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council, Palermo

Institute of Biomedicine and Molecular Immunology, IBIM, Palermo

All Listed Sponsors
lead

Stefania La Grutta, MD

OTHER

NCT02646904 - Nebulized Beclometasone Dipropionate Improves Nasal Patency in Children With Allergic Rhinitis | Biotech Hunter | Biotech Hunter